IM83 CAR-T cells

BIOLOGICAL2 trials

Sponsors

Beijing Immunochina Medical Science & Technology Co., Ltd.

Conditions

Liver CancerRecurrent OsteosarcomaRefractory Osteosarcoma

Phase 1

Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors

Beijing Immunochina Medical Science & Technology Co., Ltd.Liver Cancer

Start: 2021-08-24End: 2023-08-30Target: 12Updated: 2021-11-17

IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma

Not yet recruitingNCT06412458

Beijing Immunochina Medical Science & Technology Co., Ltd.Recurrent Osteosarcoma, Refractory Osteosarcoma

Start: 2024-06-15End: 2026-06-15Target: 9Updated: 2024-05-14